

# **Product datasheet for CF801107**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **KRAS Mouse Monoclonal Antibody [Clone ID: OTI1D1]**

#### **Product data:**

**Product Type:** Primary Antibodies

Clone Name: OTI1D1
Applications: WB

Recommended Dilution: WB 1:2000

Reactivity: Human, Mouse, Rat

Host: Mouse Isotype: IgG1

Clonality: Monoclonal

Immunogen: Full length human recombinant protein of human KRAS (NP\_203524) produced in HEK293T

cell.

Formulation: Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)

**Reconstitution Method:** For reconstitution, we recommend adding 100uL distilled water to a final antibody

concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)

**Purification:** Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography

(protein A/G)

Conjugation: Unconjugated

**Storage:** Store at -20°C as received.

**Stability:** Stable for 12 months from date of receipt.

Predicted Protein Size: 21.5 kDa

**Gene Name:** KRAS proto-oncogene, GTPase

Database Link: NP 203524

Entrez Gene 16653 MouseEntrez Gene 24525 RatEntrez Gene 3845 Human

P01116



### KRAS Mouse Monoclonal Antibody [Clone ID: OTI1D1] - CF801107

**Background:** This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a

protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two

isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

Synonyms: C-K-RAS; c-Ki-ras2; CFC2; K-RAS2A; K-RAS2B; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS;


NS3; RALD

**Protein Families:** Druggable Genome

**Protein Pathways:** Acute myeloid leukemia, Axon guidance, B cell receptor signaling pathway, Bladder cancer,

Chemokine signaling pathway, Chronic myeloid leukemia, Colorectal cancer, Dorso-ventral axis formation, Endometrial cancer, ErbB signaling pathway, Fc epsilon RI signaling pathway, Gap junction, Glioma, GnRH signaling pathway, Insulin signaling pathway, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Regulation of actin cytoskeleton, Renal cell carcinoma, T cell receptor signaling pathway, Thyroid cancer, Tight junction, VEGF signaling pathway

### **Product images:**



HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY KRAS ([RC222697], Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-KRAS. Positive lysates [LY409579] (100ug) and [LC409579] (20ug) can be purchased separately from OriGene.